Modelling schizophrenia using human induced pluripotent stem cells (original) (raw)

Nature volume 473, pages 221–225 (2011)Cite this article

Subjects

A Corrigendum to this article was published on 19 October 2011

Abstract

Schizophrenia (SCZD) is a debilitating neurological disorder with a world-wide prevalence of 1%; there is a strong genetic component, with an estimated heritability of 80–85%1. Although post-mortem studies have revealed reduced brain volume, cell size, spine density and abnormal neural distribution in the prefrontal cortex and hippocampus of SCZD brain tissue2 and neuropharmacological studies have implicated dopaminergic, glutamatergic and GABAergic activity in SCZD3, the cell types affected in SCZD and the molecular mechanisms underlying the disease state remain unclear. To elucidate the cellular and molecular defects of SCZD, we directly reprogrammed fibroblasts from SCZD patients into human induced pluripotent stem cells (hiPSCs) and subsequently differentiated these disorder-specific hiPSCs into neurons (Supplementary Fig. 1). SCZD hiPSC neurons showed diminished neuronal connectivity in conjunction with decreased neurite number, PSD95-protein levels and glutamate receptor expression. Gene expression profiles of SCZD hiPSC neurons identified altered expression of many components of the cyclic AMP and WNT signalling pathways. Key cellular and molecular elements of the SCZD phenotype were ameliorated following treatment of SCZD hiPSC neurons with the antipsychotic loxapine. To date, hiPSC neuronal pathology has only been demonstrated in diseases characterized by both the loss of function of a single gene product and rapid disease progression in early childhood4,5,6. We now report hiPSC neuronal phenotypes and gene expression changes associated with SCZD, a complex genetic psychiatric disorder.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE25673. As per our agreement with Coriell Cell Repository, all hiPSC lines generated from control and schizophrenic fibroblasts will only be available from Coriell.

References

  1. Sullivan, P. F., Kendler, K. S. & Neale, M. C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60, 1187–1192 (2003)
    Article Google Scholar
  2. Wong, A. H. & Van Tol, H. H. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 27, 269–306 (2003)
    Article Google Scholar
  3. Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G. & Hajos, M. Neurophysiological biomarkers for drug development in schizophrenia. Nature Rev. Drug Discov. 7, 68–83 (2008)
    Article CAS Google Scholar
  4. Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277–280 (2009)
    Article ADS CAS Google Scholar
  5. Lee, G. et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402–406 (2009)
    Article ADS CAS Google Scholar
  6. Marchetto, M. C. et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527–539 (2010)
    Article CAS Google Scholar
  7. Maherali, N. et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1, 55–70 (2007)
    Article CAS Google Scholar
  8. Ugolini, G. Use of rabies virus as a transneuronal tracer of neuronal connections: implications for the understanding of rabies pathogenesis. Dev. Biol. (Basel) 131, 493–506 (2008)
    CAS Google Scholar
  9. Wickersham, I. R. et al. Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53, 639–647 (2007)
    Article CAS Google Scholar
  10. Lafon, M. Rabies virus receptors. J. Neurovirol. 11, 82–87 (2005)
    Article CAS Google Scholar
  11. Selemon, L. D. & Goldman-Rakic, P. S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45, 17–25 (1999)
    Article CAS Google Scholar
  12. Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. & Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr. Bull. 36, 301–313 (2010)
    Article Google Scholar
  13. Walsh, T. et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. _Science_320 539–543 (2008)
  14. Higgs, B. W., Elashoff, M., Richman, S. & Barci, B. An online database for brain disease research. BMC Genomics 7, 70 (2006)
    Article Google Scholar
  15. Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med. 13, 1102–1107 (2007)
    Article CAS Google Scholar
  16. Patterson, S. L. et al. Some forms of cAMP-mediated long-lasting potentiation are associated with release of BDNF and nuclear translocation of phospho-MAP kinase. Neuron 32, 123–140 (2001)
    Article CAS Google Scholar
  17. Freyberg, Z., Ferrando, S. J. & Javitch, J. A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry 167, 388–396 (2010)
    Article Google Scholar
  18. Stefansson, H. et al. Large recurrent microdeletions associated with schizophrenia. Nature 455, 232–236 (2008)
    Article ADS CAS Google Scholar
  19. The International Schizophrenia Consortium . Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455, 237–241 (2008)
    Article Google Scholar
  20. Karayiorgou, M. & Gogos, J. A. The molecular genetics of the 22q11-associated schizophrenia. Brain Res. Mol. Brain Res. 132, 95–104 (2004)
    Article CAS Google Scholar
  21. Wang, X. D., Su, Y. A., Guo, C. M., Yang, Y. & Si, T. M. Chronic antipsychotic drug administration alters the expression of neuregulin 1β, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int. J. Neuropsychopharmacol. 11, 553–561 (2008)
    PubMed Google Scholar
  22. Kapur, S. et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am. J. Psychiatry 154, 1525–1529 (1997)
    Article CAS Google Scholar
  23. Cannon, T. D. & Keller, M. C. Endophenotypes in the genetic analyses of mental disorders. Annu. Rev. Clin. Psychol. 2, 267–290 (2006)
    Article Google Scholar
  24. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). (American Psychiatric Press, 1994)
    Google Scholar
  25. McCarthy, S. E. et al. Microduplications of 16p11.2 are associated with schizophrenia. Nature Genet. 41, 1223–1227 (2009)
    Article CAS Google Scholar

Download references

Acknowledgements

L. Moore, B. Miller, K. Stecker, J. Jepsen, D. Sepp, S. Larkin and L. Johnson provided technical assistance. T. Berggren directs, and M. Lutz manages, the Salk Stem Cell facility. D. Gibbs directs the Salk Viral Vector Core. J. Nguyen and L. Ouyang provided gene expression support. D. Chambers and J. Barrie provided FACS support. E. Callaway and I. Wickersham provided rabies trans-neuronal tracing viruses and invaluable advice and scientific feedback. M. Lawson provided assistance with statistical analysis. Thanks to G. Yeo, M. McConnell, S. Aigner, C. Marchetto and L. Boyer for advice and conversation. K.J.B. is supported by a training grant from the California Institute for Regenerative Medicine. The Gage Laboratory, and this project, is partially funded by CIRM Grant RL1-00649-1, The Lookout and Mathers Foundation, the Helmsley Foundation as well as Sanofi-Aventis.

Author information

Author notes

  1. Anthony Simone, Jessica Jou, Chelsea Gelboin-Burkhart and Ngoc Tran: These authors contributed equally to this work.

Authors and Affiliations

  1. Salk Institute for Biological Studies, Laboratory of Genetics, 10010 North Torrey Pines Road, La Jolla, 92037, California, USA
    Kristen J. Brennand, Anthony Simone, Jessica Jou, Chelsea Gelboin-Burkhart, Ngoc Tran, Sarah Sangar, Yan Li, Yangling Mu, Diana Yu & Fred H. Gage
  2. Department of Biology, Pennsylvania State University, 201 Life Science Building, University Park, 16802, Pennsylvania, USA
    Gong Chen
  3. Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, 11724, New York, USA
    Shane McCarthy
  4. Department of Psychiatry and Department of Cellular and Molecular Medicine, University of California San Diego, University Of California, San Diego, La Jolla, 92093, California, USA
    Jonathan Sebat

Authors

  1. Kristen J. Brennand
    You can also search for this author inPubMed Google Scholar
  2. Anthony Simone
    You can also search for this author inPubMed Google Scholar
  3. Jessica Jou
    You can also search for this author inPubMed Google Scholar
  4. Chelsea Gelboin-Burkhart
    You can also search for this author inPubMed Google Scholar
  5. Ngoc Tran
    You can also search for this author inPubMed Google Scholar
  6. Sarah Sangar
    You can also search for this author inPubMed Google Scholar
  7. Yan Li
    You can also search for this author inPubMed Google Scholar
  8. Yangling Mu
    You can also search for this author inPubMed Google Scholar
  9. Gong Chen
    You can also search for this author inPubMed Google Scholar
  10. Diana Yu
    You can also search for this author inPubMed Google Scholar
  11. Shane McCarthy
    You can also search for this author inPubMed Google Scholar
  12. Jonathan Sebat
    You can also search for this author inPubMed Google Scholar
  13. Fred H. Gage
    You can also search for this author inPubMed Google Scholar

Contributions

K.J.B. designed the experiments with F.H.G. K.J.B. completed the experiments and wrote the manuscript. A.S. contributed to the microarray analysis and qPCR experiments. J.J. established the synaptic density assay and completed the calcium transient experiments. C.G.-B. and S.S. performed most of the synaptic protein experiments. N.T. analysed the rabies data. N.T. and S.S. together counted neurites. Y.L., Y.M. and G.C. performed electrophysiology. D.Y. established the calcium transient assay. S.M.C. and J.S. completed the CNV analysis.

Corresponding author

Correspondence toFred H. Gage.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

Supplementary Information The file contains Supplementary Tables 1-8 and Supplementary Figures 1-12 with legends. This file was replaced on 19 October 2011; see accompanying corrigendum doi:10/1038 nature 10603 for details. (PDF 7519 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Brennand, K., Simone, A., Jou, J. et al. Modelling schizophrenia using human induced pluripotent stem cells.Nature 473, 221–225 (2011). https://doi.org/10.1038/nature09915

Download citation

Editorial Summary

A model for schizophrenia

Many cellular and molecular phenomena have been described in neurons of schizophrenic patients, mostly based on post-mortem data, but there is still no clear understanding of mechanisms underlying the disease. Gage and colleagues now demonstrate the feasibility of generating a human cell-based model of schizophrenia. Fibroblasts from patients with schizophrenia were reprogrammed into induced pluripotent stem cells and subsequently differentiated into neurons. These neurons displayed a number of schizophrenia-associated phenotypes, including reduced connectivity and altered gene expression, some of which could be rescued by an antipsychotic.